These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 18495609)

  • 1. [Inhibitory effect of sorafenib combined with arsenic trioxide on hepatocellular carcinoma cells].
    Wu J; Luo RC; Zhang H; Cui YZ
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Apr; 28(4):639-41. PubMed ID: 18495609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Coadministration of sorafenib and cisplatin inhibits proliferation of hepatocellular carcinoma HepG2 cells in vitro].
    Chen FS; Cui YZ; Luo RC; Wu J; Zhang H
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug; 28(9):1684-7. PubMed ID: 18819900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma.
    Ou DL; Shen YC; Liang JD; Liou JY; Yu SL; Fan HH; Wang DS; Lu YS; Hsu C; Cheng AL
    Clin Cancer Res; 2009 Sep; 15(18):5820-8. PubMed ID: 19737956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vitamin K enhancement of sorafenib-mediated HCC cell growth inhibition in vitro and in vivo.
    Wei G; Wang M; Hyslop T; Wang Z; Carr BI
    Int J Cancer; 2010 Dec; 127(12):2949-58. PubMed ID: 21351273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential effects of arsenic trioxide on chemosensitization in human hepatic tumor and stellate cell lines.
    Rangwala F; Williams KP; Smith GR; Thomas Z; Allensworth JL; Lyerly HK; Diehl AM; Morse MA; Devi GR
    BMC Cancer; 2012 Sep; 12():402. PubMed ID: 22963400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC).
    Huynh H; Ngo VC; Koong HN; Poon D; Choo SP; Toh HC; Thng CH; Chow P; Ong HS; Chung A; Goh BC; Smith PD; Soo KC
    J Hepatol; 2010 Jan; 52(1):79-87. PubMed ID: 19910069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
    Liu L; Cao Y; Chen C; Zhang X; McNabola A; Wilkie D; Wilhelm S; Lynch M; Carter C
    Cancer Res; 2006 Dec; 66(24):11851-8. PubMed ID: 17178882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study.
    Zhang Z; Zhou X; Shen H; Wang D; Wang Y
    BMC Med; 2009 Aug; 7():41. PubMed ID: 19698189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel combination of withaferin A and sorafenib shows synergistic efficacy against both papillary and anaplastic thyroid cancers.
    Cohen SM; Mukerji R; Timmermann BN; Samadi AK; Cohen MS
    Am J Surg; 2012 Dec; 204(6):895-900; discussion 900-1. PubMed ID: 23231932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PTEN enhances the sensitivity of human hepatocellular carcinoma cells to sorafenib.
    Ruan ZP; Xu R; Lv Y; Tian T; Wang WJ; Guo H; Nan KJ
    Oncol Res; 2012; 20(2-3):113-21. PubMed ID: 23193917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiosensitivity enhancement of human hepatocellular carcinoma cell line SMMC-7721 by sorafenib through the MEK/ERK signal pathway.
    Dai XF; Ding J; Zhang RG; Ren JH; Ma CM; Wu G
    Int J Radiat Biol; 2013 Sep; 89(9):724-31. PubMed ID: 23682582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of doxorubicin-induced autophagy in hepatocellular carcinoma Hep3B cells by sorafenib--the role of extracellular signal-regulated kinase counteraction.
    Manov I; Pollak Y; Broneshter R; Iancu TC
    FEBS J; 2011 Sep; 278(18):3494-507. PubMed ID: 21790999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
    Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Evers BM
    J Surg Res; 2012 Aug; 176(2):542-8. PubMed ID: 22261591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sorafenib induces growth inhibition and apoptosis in human synovial sarcoma cells via inhibiting the RAF/MEK/ERK signaling pathway.
    Peng CL; Guo W; Ji T; Ren T; Yang Y; Li DS; Qu HY; Li X; Tang S; Yan TQ; Tang XD
    Cancer Biol Ther; 2009 Sep; 8(18):1729-36. PubMed ID: 19633425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. pERK/pAkt phenotyping in circulating tumor cells as a biomarker for sorafenib efficacy in patients with advanced hepatocellular carcinoma.
    Li J; Shi L; Zhang X; Sun B; Yang Y; Ge N; Liu H; Yang X; Chen L; Qian H; Wu M; Yin Z
    Oncotarget; 2016 Jan; 7(3):2646-59. PubMed ID: 26544731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Schedule-dependent antitumor effects of 5-fluorouracil combined with sorafenib in hepatocellular carcinoma.
    Deng L; Ren Z; Jia Q; Wu W; Shen H; Wang Y
    BMC Cancer; 2013 Jul; 13():363. PubMed ID: 23895220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Schedule-dependent effects of sorafenib in combination with paclitaxel on human hepatocellular carcinoma cell line BEL-7402].
    Li N; Zhang Y; Wu T; Li M
    Ai Zheng; 2009 Aug; 28(8):838-43. PubMed ID: 19664330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts.
    Beljanski V; Lewis CS; Smith CD
    Cancer Biol Ther; 2011 Mar; 11(5):524-34. PubMed ID: 21258214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bufalin enhances the anti-proliferative effect of sorafenib on human hepatocellular carcinoma cells through downregulation of ERK.
    Gao Y; Li HX; Xu LT; Wang P; Xu LY; Cohen L; Yang PY; Gu K; Meng ZQ
    Mol Biol Rep; 2012 Feb; 39(2):1683-9. PubMed ID: 21617941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MK2206 overcomes the resistance of human liver cancer stem cells to sorafenib by inhibition of pAkt and upregulation of pERK.
    Zhai B; Zhang X; Sun B; Cao L; Zhao L; Li J; Ge N; Chen L; Qian H; Yin Z
    Tumour Biol; 2016 Jun; 37(6):8047-55. PubMed ID: 26711788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.